AU2018255191B2 - Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds - Google Patents

Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds Download PDF

Info

Publication number
AU2018255191B2
AU2018255191B2 AU2018255191A AU2018255191A AU2018255191B2 AU 2018255191 B2 AU2018255191 B2 AU 2018255191B2 AU 2018255191 A AU2018255191 A AU 2018255191A AU 2018255191 A AU2018255191 A AU 2018255191A AU 2018255191 B2 AU2018255191 B2 AU 2018255191B2
Authority
AU
Australia
Prior art keywords
compound
methyl
amino
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018255191A
Other languages
English (en)
Other versions
AU2018255191A1 (en
Inventor
Marta Maria CIFUENTES-GARCIA
Maria Cristina GARCIA-PAREDES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2018255191A1 publication Critical patent/AU2018255191A1/en
Application granted granted Critical
Publication of AU2018255191B2 publication Critical patent/AU2018255191B2/en
Priority to AU2022206702A priority Critical patent/AU2022206702B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2018255191A 2017-04-18 2018-04-11 Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds Active AU2018255191B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022206702A AU2022206702B2 (en) 2017-04-18 2022-07-18 Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17382207 2017-04-18
EP17382207.3 2017-04-18
PCT/US2018/027005 WO2018194885A1 (en) 2017-04-18 2018-04-11 Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022206702A Division AU2022206702B2 (en) 2017-04-18 2022-07-18 Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds

Publications (2)

Publication Number Publication Date
AU2018255191A1 AU2018255191A1 (en) 2019-11-07
AU2018255191B2 true AU2018255191B2 (en) 2022-04-21

Family

ID=58606227

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018255191A Active AU2018255191B2 (en) 2017-04-18 2018-04-11 Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
AU2022206702A Active AU2022206702B2 (en) 2017-04-18 2022-07-18 Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022206702A Active AU2022206702B2 (en) 2017-04-18 2022-07-18 Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds

Country Status (30)

Country Link
US (2) US11655214B2 (https=)
EP (2) EP4039675B1 (https=)
JP (2) JP7110232B2 (https=)
KR (2) KR102575246B1 (https=)
CN (2) CN117510405A (https=)
AU (2) AU2018255191B2 (https=)
BR (1) BR112019021867A2 (https=)
CO (1) CO2019012767A2 (https=)
CR (1) CR20190519A (https=)
CY (1) CY1125150T1 (https=)
DK (2) DK4039675T3 (https=)
ES (2) ES2988739T3 (https=)
FI (1) FI4039675T3 (https=)
HR (2) HRP20220263T1 (https=)
HU (2) HUE057745T2 (https=)
IL (2) IL270005B (https=)
LT (2) LT3612519T (https=)
MX (2) MX389724B (https=)
MY (1) MY199442A (https=)
NZ (1) NZ758291A (https=)
PH (1) PH12019502363B1 (https=)
PL (2) PL4039675T3 (https=)
PT (2) PT4039675T (https=)
RS (2) RS65914B1 (https=)
SA (1) SA519410320B1 (https=)
SG (1) SG11201909680UA (https=)
SI (2) SI4039675T1 (https=)
SM (2) SMT202400357T1 (https=)
WO (1) WO2018194885A1 (https=)
ZA (1) ZA201906811B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4039675T3 (pl) 2017-04-18 2025-01-07 Eli Lilly And Company Związki fenylo-2-hydroksyacetyloamino-2-metylo-fenylowe
US20210121527A1 (en) * 2018-03-26 2021-04-29 Icahn School Of Medicine At Mount Sinai Methods of treating minimal residual cancer
EP4021893A1 (en) * 2019-08-29 2022-07-06 Hibercell, Inc. Perk inhibiting compounds
US20220356186A1 (en) * 2019-08-29 2022-11-10 Hibercell, Inc. Perk inhibiting pyrrolopyrimidine compounds
WO2021041976A1 (en) 2019-08-29 2021-03-04 Hibercell, Inc. Perk inhibiting indolinyl compounds
US12331054B2 (en) 2019-08-29 2025-06-17 Hibercell, Inc. Perk inhibiting imidazolopyrazine compounds
WO2021231788A1 (en) * 2020-05-13 2021-11-18 Hibercell, Inc. Perk inhibiting pyrrolopyrimidine compounds to treat viral infections
WO2021231782A1 (en) * 2020-05-13 2021-11-18 Hibercell, Inc. Perk inhibitors for treating viral infections
CN113234029B (zh) * 2021-05-25 2022-03-22 白银康寓信生物科技有限公司 一种2-氨基-3,5-二卤代吡嗪的合成方法
AU2024242199A1 (en) * 2023-03-30 2025-10-30 Hibercell, Inc. Crystalline forms of (r)-2-amino-5-(4-(2-(3,5-difluorophenyl)-2-hydroxyacetamido)-2-methylphenyl)-n-isopropylnicotinamide and methods for using the same
GB202407386D0 (en) 2024-05-24 2024-07-10 Apollo Ap45 Ltd 1H-pyrazolo(4,3-D)pyrimidine derivatives

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170022206A1 (en) * 2015-07-24 2017-01-26 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit and pdfgr

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
DK0970084T3 (da) 1997-03-19 2003-09-29 Abbott Gmbh & Co Kg Pyrrolo[2,3-d]pyrimidiner og deres anvendelse som inhibitorer for tyrosinkinase
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
EP1501514B1 (en) * 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
EA010485B1 (ru) * 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
WO2005030933A2 (en) 2003-09-24 2005-04-07 Genera Doo Bone morphogenetic protein (bmp)-7 based diagnosis and treatment of cancer
PE20070335A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
US8211919B2 (en) * 2005-09-02 2012-07-03 Astellas Pharma Inc. Amide derivatives as rock inhibitors
NZ617520A (en) 2008-02-25 2015-05-29 Nestec Sa Drug selection for breast cancer therapy using antibody-based arrays
US20120014911A1 (en) 2009-01-09 2012-01-19 Serge Fuchs Regulators of the Interferon-Alpha Receptor 1 (IFNAR1) Chain of the Interferon Receptor
CA2794153C (en) 2010-03-25 2018-01-02 Glaxosmithkline Llc Substituted indoline derivatives as perk inhibitors
EP2986286A1 (en) 2013-04-15 2016-02-24 Universita' Degli Studi di Bari Galloyl benzamide-based compounds as jnk modulators
WO2015056180A1 (en) 2013-10-15 2015-04-23 Glaxosmithkline Intellectual Property (No.2) Limited Indoline derivatives as inhibitors of perk
WO2015068767A1 (ja) 2013-11-08 2015-05-14 小野薬品工業株式会社 ピロロピリミジン誘導体
WO2015136463A1 (en) 2014-03-11 2015-09-17 Glaxosmithkline Intellectual Property (No.2) Limited Chemical compounds acting as perk inhibitors
WO2016004254A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
ES2792036T3 (es) 2014-11-14 2020-11-06 Nerviano Medical Sciences Srl Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de cinasa
GB201508747D0 (en) 2015-05-21 2015-07-01 Univ Edinburgh Compounds
CN109153680B (zh) 2016-07-07 2021-04-23 株式会社大熊制药 4-氨基吡唑并[3,4-d]嘧啶基氮杂双环衍生物及含其的药物组合物
JP2019521166A (ja) 2016-07-20 2019-07-25 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｐｅｒｋ阻害剤としてのイソキノリン誘導体
CN106748989B (zh) 2016-11-14 2020-03-17 西安交通大学 一种具有抗肿瘤活性的二芳基脲类化合物及其制备方法和应用
US20190388426A1 (en) 2017-01-30 2019-12-26 Université de Liège Perk and ire-1a inhibitors against neurodevelopmental disorders
PL4039675T3 (pl) 2017-04-18 2025-01-07 Eli Lilly And Company Związki fenylo-2-hydroksyacetyloamino-2-metylo-fenylowe
JP7304855B2 (ja) 2017-11-14 2023-07-07 ザ チルドレンズ メディカル センター コーポレーション 新規イミダゾピリミジン化合物およびそれらの使用
EP3492454A1 (en) 2017-11-30 2019-06-05 Step Pharma S.A.S. Compounds
US20210121527A1 (en) 2018-03-26 2021-04-29 Icahn School Of Medicine At Mount Sinai Methods of treating minimal residual cancer
US11186579B2 (en) 2018-07-06 2021-11-30 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
US20220040183A1 (en) 2018-10-01 2022-02-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of inhibitors of stress granule formation for targeting the regulation of immune responses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170022206A1 (en) * 2015-07-24 2017-01-26 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit and pdfgr

Also Published As

Publication number Publication date
SMT202400357T1 (it) 2024-11-15
JP2021517555A (ja) 2021-07-26
US20230373922A1 (en) 2023-11-23
HRP20220263T1 (hr) 2022-04-29
JP7110232B2 (ja) 2022-08-01
KR20190140966A (ko) 2019-12-20
RS62933B1 (sr) 2022-03-31
CN110831927A (zh) 2020-02-21
EP3612519A1 (en) 2020-02-26
US11655214B2 (en) 2023-05-23
SA519410320B1 (ar) 2022-05-08
KR20230129627A (ko) 2023-09-08
EP3612519B1 (en) 2021-12-01
PL4039675T3 (pl) 2025-01-07
CY1125150T1 (el) 2023-06-09
MX2022001310A (es) 2022-03-02
CN110831927B (zh) 2023-07-14
LT3612519T (lt) 2022-03-25
SMT202200100T1 (it) 2022-03-21
EP4039675B1 (en) 2024-06-12
MY199442A (en) 2023-10-28
ES2906847T3 (es) 2022-04-20
RU2019136694A (ru) 2021-05-18
AU2022206702A1 (en) 2022-08-11
SG11201909680UA (en) 2019-11-28
US12590064B2 (en) 2026-03-31
HRP20241188T1 (hr) 2024-12-06
CO2019012767A2 (es) 2020-04-01
PT3612519T (pt) 2022-02-22
AU2022206702B2 (en) 2024-04-11
WO2018194885A1 (en) 2018-10-25
MX389724B (es) 2025-03-20
AU2018255191A1 (en) 2019-11-07
PH12019502363A1 (en) 2020-12-07
JP7331212B2 (ja) 2023-08-22
RS65914B1 (sr) 2024-10-31
PT4039675T (pt) 2024-09-16
NZ758291A (en) 2025-11-28
DK3612519T3 (da) 2022-03-07
SI3612519T1 (sl) 2022-04-29
FI4039675T3 (fi) 2024-09-10
DK4039675T3 (da) 2024-09-02
EP4039675A1 (en) 2022-08-10
CA3060564A1 (en) 2018-10-25
MX2019012428A (es) 2022-01-28
CR20190519A (es) 2020-03-06
BR112019021867A2 (pt) 2020-05-26
HUE068023T2 (hu) 2024-12-28
IL288822B2 (en) 2023-06-01
IL288822A (en) 2022-02-01
ES2988739T3 (es) 2024-11-21
HUE057745T2 (hu) 2022-06-28
US20210114985A1 (en) 2021-04-22
CN117510405A (zh) 2024-02-06
PL3612519T3 (pl) 2022-05-02
RU2019136694A3 (https=) 2021-05-19
ZA201906811B (en) 2021-01-27
LT4039675T (lt) 2024-10-10
JP2022141835A (ja) 2022-09-29
KR102575246B1 (ko) 2023-09-06
PH12019502363B1 (en) 2023-11-15
IL270005B (en) 2022-01-01
SI4039675T1 (sl) 2024-10-30

Similar Documents

Publication Publication Date Title
AU2022206702B2 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
KR101813830B1 (ko) 친전자성 작용기를 갖는 헤테로아릴 피리돈 및 아자-피리돈 화합물
RU2537945C2 (ru) Триазиновые, пиримидиновые и пиридиновые аналоги и их применение в качестве терапевтических агентов и диагностических проб
CN101883764B (zh) 吡唑衍生物及其作为细胞周期蛋白依赖性激酶抑制剂的用途
JP6114820B2 (ja) プテリジノン誘導体およびｅｇｆｒ、ｂｌｋ、ｆｌｔ３の阻害剤としての応用
JP7477846B2 (ja) Ｎを含むヘテロアリール誘導体およびこれを有効成分として含むがんの予防または治療用薬学的組成物
JP2018508563A (ja) Ｕｓｐ７阻害剤化合物及び使用方法
US10577354B2 (en) Bis-pyridazine compounds and their use in treating cancer
CA3060564C (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
HK40079392B (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
HK40079392A (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
RU2804280C2 (ru) Фенил-2-гидрокси-ацетиламино-2-метил-фениловые соединения
HK40024453A (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
HK40024453B (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
WO2023187471A1 (en) Heteroaryl derivative compounds, and uses thereof
KR20250041906A (ko) Hpk1 및 mlk3 저해 활성을 갖는 신규한 화합물 및 이를 함유하는 항암용 조성물
KR20230142000A (ko) 아이소옥사졸리딘 유도체 화합물 및 이의 용도

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)